Health economics of skin cancer

Similar documents
Eshini Perera 1,2, Sean McGuigan 2, Rodney Sinclair 2,3

Lessons learned from the Australian experience: controlling for the damaging effects of ultraviolet rays

Public Health Association of Australia: Policy-at-a-glance Skin Cancer Prevention Policy

Innovations in Immunotherapy - Melanoma. Systemic Therapies October 27, 2018 Charles L. Bane, MD

Andrew Lee Kieran Benjamin Garbutcheon-Singh Shreya Dixit Pam Brown Saxon D. Smith

23/04/2015. Recent advances in Melanoma and Non Melanoma Skin Cancer

Epidemiological and economic impact of potential increased hepatitis C treatment uptake in Australia

Sunscreens and cutaneous neoplasia:

Skin Cancer. 5 Warning Signs. American Osteopathic College of Occupational and Preventive Medicine OMED 2012, San Diego, Monday, October 8, 2012 C-1

fluorouracil 0.5% / salicylic acid 10% cutaneous solution (Actikerall ) SMC No. (728/11) Almirall S.A.

SQUAMOUS CELL CARCINOMA

Disclosures. Melanoma and Non melanoma Skin Cancer: What You Need to Know. I have no conflicts of interest to disclose

Dermatology for the PCP Deanna G. Brown, MD, FAAD Susong Dermatology Consulting Staff at CHI Memorial

Single Technology Appraisal (STA) Nivolumab for adjuvant treatment of resected stage III and IV melanoma

Nonmelanoma skin cancers

Epidemiology. Objectives 8/28/2017

Black is the New Black or How I learned to stop worrying and love melanoma (with apologies to Dr. Strangelove)

We are a dedicated skin clinic with specialized equipments and staff. We only deal with skin and skin cancer.

Cutaneous Malignancies: A Primer COPYRIGHT. Marissa Heller, M.D.

Sun Protection and Outdoor Workers

GP Update Non-Melanoma Skin Cancer. Mark Strickland, SunSmart Manager Cancer Council Western Australia Thursday 8 th December 2016

Expected Non Melanoma Skin (Keratinocytic) Cancer incidence in New Zealand for 2018

Actinic Keratoses and Bowen s disease

Melanoma: Early Detection and Therapeutic Progress

Global Best Practices in Tobacco Control

QUEENSLAND. Public Health Forum. Under the. Queensland Sun

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Single Technology Appraisal (STA) Dabrafenib for treating unresectable, advanced or metastatic

Access to cancer drugs: The role for a stakeholder alliance?

Breast Cancer Network Australia DXA bone mineral density survey May 2012

Basal cell carcinoma

Useful tools, references and contacts

How can we reduce the mortality from melanoma in Australia?

Global Skin Cancer Diagnosis and Therapeutics Market Research and Forecast

Know who is at risk: LOOK! for ABCDs, rapidly changing lesions, do a biopsy when indicated

2002 AUSTRALIAN BUREAU OF STATISTICS DATA ON ACCIDENTAL DRUG-INDUCED DEATHS DUE TO OPIOIDS

Hepatitis B from targeted screening and immunisation of migrant mothers to universal immunisation in Australia

Current Trends in Melanoma Theresa Medina, MD UCD Cutaneous Oncology

Greg Cook Associate Director, Market Access, Bristol-Myers Squibb Australia

Skin Cancer - Non-Melanoma

BL-5010P A NOVEL PRE-FILLED APPLICATOR FOR THE NON-SURGICAL REMOVAL OF SKIN LESIONS

Reducing the impact of skin cancer in NSW Strategic Plan

Making Diabetes Prevention a Reality: The National Diabetes Prevention Program

AN OPTIMAL REGULATORY MIX FOR METHAMPHETAMINE PRECURSORS?

Monitoring hepatitis C treatment uptake in Australia

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE

eviq.org.au A/Prof Jeremy Shapiro Cabrini Hematology and Oncology Centre Chair EVIQ Medical Oncology Committee PCPA 2017 Jeremy Shapiro

Talking to Your Clients About Skin Cancer. Objectives 9/9/2017. Amanda Friedrichs, MD, FAAD AMTA National Conference September 14, 2017

Clinical Practice Guide. Basal cell carcinoma, squamous cell carcinoma (and related lesions) a guide to clinical management in Australia

Session 3: Optimising ehealth: Strategy, Technology, Mangement

DR JANE MFR, LESLEY WILKES AND JESS HARTCHER-O'IBRIEN

The state of asthma in South Australia

General information about skin cancer

Corporate Medical Policy

Regeneron and Sanofi are financial supporters of The Skin Cancer Foundation and collaborated in the development of this article. US-ONC /2018

UVR Protection and Vitamin D

PharmaTimes EDITED BY JENNY HONE/CLAIRE BOWIE

Skin cancer in Australia

Skin Cancer 101: Diagnosis and Management of the Most Common Cancer

The Role of Media in Influencing Policy

CHAPTER 4 METHOD AND LOCATION OF DIALYSIS. Nancy Briggs Kylie Hurst Stephen McDonald Annual Report 35th Edition

Patient Leader Education Summit. Precision Medicine: Today and Tomorrow March 31, 2017

Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment

Measuring current and future cost of skin cancer in England

Demonstrating the Power of Umbrella Branding in the Charitable Sector

Keytruda. Keytruda (pembrolizumab) Description

Identifying Skin Cancer. Mary S. Stone MD Professor of Dermatology and Pathology University of Iowa Carver College of Medicine March, 2018

The Plastic Surgery See and Treat Skin Cancer Clinic (SATSKIN)

The Galectin-3 Inhibitor GR-MD-02 for Combination Cancer Immunotherapy

SUN, SAVVY AND SKIN : A REVIEW OF SKIN CANCER IN SOUTH AFRICA AND BEYOND

Large majority caused by sun exposure Often sun exposure before age 20 Persons who burn easily and tan poorly are at greatest risk.

Accidental drug-induced deaths due to opioids in Australia, 2013

Comprehensive Tobacco Control Programs: Economic Review. Page 1 of 26. Study Info Intervention Characteristics Population Characteristics

New paradigms for treating metastatic melanoma

Metastatic Melanoma. Cynthia Kwong February 16, 2017 SUNY Downstate Medical Center Department of Surgery Grand Rounds

Periocular skin cancer

ACAPMA Tobacco Compliance Webinar powered by ACAPMAcademy. This webinar will commence at 11:00am ESDT, thank you for joining us

Dementia in Australia

Disclosures. I have no conflicts of interest to disclose

Opdivo. Opdivo (nivolumab) Description

Advancing Access to Newer Treatments for Atrial Fibrillation. Canadian Cardiovascular Society Congress October 24, 2010 Montreal, Canada

Checkpoint regulators a new class of cancer immunotherapeutics. Dr Oliver Klein Medical Oncologist ONJCC Austin Health

Cost-effectiveness of nivolumab with ipilimumab (Opdivo with Yervoy ) for the treatment of advanced (unresectable or metastatic) melanoma.

Yervoy. Yervoy (ipilimumab) Description

Learning Objectives. Tanning. The Skin. Classic Features. Sun Reactive Skin Type Classification. Skin Cancers: Preventing, Screening and Treating

Melanoma. Exceptional healthcare, personally delivered

We re on the Web! Visit us at

Moving Forward with the Surgeon General s Call to Action to Prevent Skin Cancer

Yervoy. Yervoy (ipilimumab) Description

METVIX PDT ON THE MARKET IN GERMANY AND UK

Palliative Care and End of Life Care

Contrast with Australian Guidelines A/Pr Pascale Guitera,

Skin Cancer. Dr Elizabeth Ogden Associate Specialist in Dermatology East and North Herts Dr Elizabeth Ogden

The Health Care Costs Of Skin Cancer Caused By Ultraviolet Radiation By James R. Vernon

Could a national skin cancer primary prevention campaign in Australia be worthwhile?: an economic perspective

Risks of alcohol-attributable hospitalisation and death in Australia over time: Evidence of divergence by region, age and sex

Dermatological Manifestations in the Elderly. Sanjay Siddha Staff Dermatologist UHN & MSH

Oral and Maxillofacial Surgery Department

Advanced Skin Cancer and Melanoma

National AIDS Registry

Transcription:

Health economics of skin cancer Louisa Gordon louisa.gordon@qimrberghofer.edu.au Sunscreen Summit QIMRB 19 Mar 2018

Outline Cost burden of skin cancer Investment in skin cancer prevention Evidence for primary prevention cost-effectiveness The market for sunscreen

The full burden of UV sun-damaged skin MEDICARE pays for: biopsy, histopathology, surgical excision, cryotherapy, multiple GP & specialist visits, curettage, topical creams (via PBS) radiotherapy, chemotherapy, scans skin flaps/grafting, Mohs surgery, Immunotherapies (melanoma) OTHER: photodynamic therapy, hydroxy-acid peels, dermabrasion, interferon-alpha therapy 13,000 Melanomas 750,000 SCC/BCC Solar keratoses & benign lesions Photo-ageing skin damage Source: https://wiki.cancer.org.au/skincancerstats/

Health system costs of melanoma Cost for diagnosis & treatment of all new cases of melanomas per year = $201 million 5% Metastatic 8% Stage III resectable $115,109 per case $37,729 per case 87% Stage 0 (in situ), I, II $1,681 per case Source: Elliott T, Olsen C, Whiteman DC, Gordon LG. Estimated healthcare costs of melanoma in Australia over 3 years post diagnosis. Applied Health Economics and Health Policy. 2017 1-12;

New medicines for advanced melanoma Name Brand PBAC Decision 2016 cost Ipilimumab Yervoy Approved Nov 2012 $24.9 million Dabrafenib Tafinlar Approved 2013 $50.8 million Trametinib Mekinist Approved: June 2015 $50.4 million Pembrolizumab Keytruda Approved: June 2015 $119.0 million Nivolumab Opdivo Approved: May 2016 $3.9 million Vemurafenib Zelboraf Approved: March 2016 $925,693 Adverse events: add ~$10,000 per patient Source: Medicare item reports http://medicarestatistics.humanservices.gov.au/statistics

Health system costs of keratinocyte (or nonmelanoma) skin cancers Cost for treatment of basal cell carcinomas and squamous cell carcinomas = $703 million Total no. of excisions for BCC/SCC in 2016 = 626,759 12,053 excisions per week 301 per business hour Fransen M, Karahalios A, Sharma N, English DR, Giles GG, Sinclair RD. Non-melanoma skin cancer in Australia. Med J Aust 2012 Nov 19;197(10):565-8

Number of excisions of BCC/SCC per 100,000 persons (MBS items 31255 to 31290) 5000 4500 4000 Total in 2006 = 2168 Total in 2016 = 2552 3500 3000 2500 2000 2006 2016 18% increase 1500 1000 500 0 NSW VIC QLD SA WA TAS ACT NT Source: Medicare item reports http://medicarestatistics.humanservices.gov.au/statistics

High burden in individuals with multiple skin cancers 10,000 539 participants with MM (11% had 2 MMs) 5,134 participants with KCs (10% had 6 KCs) Frequency 1,000 100 10 GP bulk-billing rate 34-60% (lower if multiples) 1 1 2 3 4 5 6 7 8 9 10 1112 13 14 15 1617 18 19 2021 22 23 2425 27 30 31 3435 50 54 No. of keratinocyte cancers per person (over average 3 years) Source: Gordon LG et al. Multiplicity of skin cancers in Queensland and their cost burden to government and patients. ANZJPH 2018; 42(1):86-91.

Biopsy (MBS item 30071) - total in 2017 = 1.2 million TAS 2% ACT 1% NT 0% WA 9% 4,535 per 100,000 persons SA 4% NSW 31% Costing Medicare $43.5 million QLD 36% VIC 17% Source: Medicare item reports http://medicarestatistics.humanservices.gov.au/statistics

Hospitalisations for sunburn Source: Hospital Morbidity Data Cubes online ICD-9-CM codes 692.71, 692.76, 696.77 & ICD-10-AM L55

How much do we invest in skin cancer prevention? Australia & NZ Australian Government 2006-07 National Skin Cancer Awareness Campaign VicHealth on SunSmart over 25 years Vic Govt 2013-15 CINSW 2007-2011 Dark Side Tanning & Wes Bonney campaigns NSW & Qld 1998-2006 SunSmart, WA over long term Vic DoH, Cancer Councils - shade creation grants Cancer Council Australia 2014 shade creation, EFTPOS Giveback NZ Cancer Society in 2007/2008 on multi component, multi-media campaign Funding $21 million $16 million $14 million $15.6 million $0.08 pp $0.90 pp $5 million $1 million NZ $2 million 2018 Cancer Council WA SunSmart $825,000 No national funding on skin cancer prevention for a decade

Evidence for the cost-effectiveness of primary prevention Study Intervention Results Cost-effective? Cristofolini 1992 Health campaign (Italy) $400 per life year saved, RoI YES $3.80 Garrantini 1996 Educational campaign (Italy) US$3357 per life year saved YES Kyle 2008 School-based program (US) Cost savings $12m, RoI $2-$4 YES Hirst 2009 Solaria regulation (Aus) Cost saving $9.9m YES Shih 2009 SunSmart multifaceted (Aus) Cost saving $180m, RoI $2.32 YES Gordon 2009 Sunscreen SCC/BCC (Aus) Cost saving $88K for n=812 YES Hirst 2012 Sunscreen Melanoma (Aus) $40,890 per QALY YES Shih 2015 SunSmart Victoria (Aus) Cost saving RoI $3.20 / 36c Prev YES vs $9 Tx Perez 2015 Mass-media NSW (Aus) Cost saving RoI $3.85 YES Pil 2015 Prim/sec prevention (Belgium) Cost saving / cost effective YES Source: Gordon & Rowell 2015 Euro J Can Prev, Perez 2015, Pil 2015

Evidence for the cost-effectiveness of secondary prevention Study Intervention Results Girgis 1996 (Aus) Screening persons over 50 yrs by GP every 2 years Freedberg 1999 (US) Screening high-risk by dermatologist, 1 time screen Beddingfield 2003 Screening 1-time (US) Losina 2007 (US) Screening general population Gordon 2017 (Aus) Self skin check program for men over 50 years Watts 2017 (Aus) Specialised surveillance in high risk melanoma patients $12,137 per LYS(1996) $39,600 per LYS(1996) $51,481 per LYS $80,700 per QALY Dominated Dominating win win Source: Gordon & Rowell 2015 Euro J Can Prev

The market for sunscreen Source: Sun Care in Australia Euromonitor International May 2017

12% 10% Sun care products Average growth % in value 10.6% Past 2011-16 Forecast 2016-21 8% 7% 6.7% 6% 5.6% 4.4% 4% Source: Sun Care in Australia Euromonitor International May 2017 2% 3.1% 2.2% 1.9% 0% Aftersun Self-Tanning Sun Protection Baby/child specific

Sunscreen market other points Sunscreen products had double digit growth in 2013 when SPF50+ approved by TGA Self-tanning products fastest growing category - Bondi Sands was 2016 leader - dark self-tanning products are popular Manufacturers are investing in new product innovation offering convenience, moisture and light feel. Mass brands represent 89% retail sales supermarkets, discount pharmacies Unit prices may increase following ban on animal testing July 2017 Source: Sun Care in Australia Euromonitor International May 2017

Conclusions Treatment spending far exceeds prevention investment Skin cancer prevention is highly cost-effective Australian sunscreen market data reveals a strong switch to self-tanning behaviours Sunscreen promotion offers a strong case for benefits and cost-savings at the population level (and is more important than shifting the tip of the iceberg)

Thank you for listening